Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy
AUTOR(ES)
Azzouz, Mimoun
FONTE
American Society for Clinical Investigation
RESUMO
Spinal muscular atrophy (SMA) is a frequent recessive autosomal disorder. It is caused by mutations or deletion of the telomeric copy of the survival motor neuron (SMN) gene, leading to depletion in SMN protein levels. The treatment rationale for SMA is to halt or delay the degeneration of motor neurons, but to date there are no effective drug treatments for this disease. We have previously demonstrated that pseudotyping of the nonprimate equine infectious anemia virus (using the lentivector gene transfer system) with the glycoprotein of the Evelyn-Rokitnicki-Abelseth strain of the rabies virus confers retrograde axonal transport on these vectors. Here, we report that lentivector expressing human SMN was successfully used to restore SMN protein levels in SMA type 1 fibroblasts. Multiple single injections of a lentiviral vector expressing SMN in various muscles of SMA mice restored SMN to motor neurons, reduced motor neuron death, and increased the life expectancy by an average of 3 and 5 days (20% and 38%) compared with LacZ and untreated animals, respectively. Further extension of survival by SMN expression constructs will likely require a knowledge of when and/or where high levels of SMN are needed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=535071Documentos Relacionados
- SMN Dosage Analysis and Risk Assessment for Spinal Muscular Atrophy
- Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy
- SMN mutants of spinal muscular atrophy patients are defective in binding to snRNP proteins
- A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy
- Coilin forms the bridge between Cajal bodies and SMN, the Spinal Muscular Atrophy protein